ReviewFrontiers in oncology2026
The role of MiRNA-mediated tumor microenvironment in bone metastasis from a multi-omics perspective: cross-cancer mechanisms and clinical translation.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone metastasis is a highly prevalent complication in patients with advanced prostate, breast, and lung cancers, which significantly affects the patient's prognosis. In recent years, the integration of multi-omics technologies has provided unprecedented insights into the systematic analysis of the highly heterogeneous tumor microenvironment at a systemic level. This review begins with a cross-cancer comparison, systematically outlining the functional similarities and differences in key microenvironment components (e.g., tumor-associated macrophages, cancer-associated fibroblasts, osteoclasts, and T cells) in bone metastasis across these three cancer types. It emphasizes how miRNAs mediate intercellular communication via exosomes to coordinately regulate immune evasion, stromal activation, and bone metabolic reprogramming. We further explored the translational potential of miRNA-based liquid biopsies (e.g., miR-141-3p and miR-34a) for diagnosing and prognosticating bone metastasis in breast, prostate, and lung cancers. Finally, this article looks ahead at how integrating multi-omics data with AI predictive models can overcome current delivery and safety challenges, advancing miRNA research towards the ultimate goal of precision medicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.